Administration & Faculty

Fawzy A. Elbarbry, RPh, PhD

Associate Professor

503-352-7356
fawzy.elbarbry@pacificu.edu

 

Education

2010 Foreign Pharmacy Graduate

Examination Certificate (FPGEC),                                      

National Association of Boards of Pharmacy

2006 Postdoctoral Fellow

Dept. of Medicine,

University of Saskatchewan, Canada

2006 Doctor of Philosophy,

Pharmacy, Drug Metabolism,

and Pharmacokinetics,

University of Saskatchewan, Canada

2002 Master of Science,

Analytical Chemistry,

College of Pharmacy,

University of Tanta, Egypt

1995 Postgraduate Diploma,

Analytical Chemistry,

College of Pharmacy,

University of Tanta, Egypt

1993 Bachelor of Pharmaceutical Sciences,

College of Pharmacy,

University of Tanta, Egypt

 

Areas of Research & Specialization

My research interests revolve around minimizing toxicity and/or drug interactions of xenobiotics through better understanding of their effect on drug metabolizing enzymes (DME), especially Cytochrome P450 (CYP) enzymes.  Although CYP enzymes normally generate metabolites with diminished biological activity, there are numerous examples where these enzymes mediate the formation of reactive intermediates from chemically inert agents.  These reactive metabolites play a key step in initiating cellular damage and cancers.  Modification of the activity or expression level of CYP enzymes through exposure to environmental toxins, drugs, or even herbal remedies could potentially affect the clinical outcome of concomitantly-administered drugs.  My research interest focuses on identifying the role of CYP enzymes in toxicity induced by drugs, herbal remedies and environmental toxins.  Along with the mission of Pacific University and the School of Pharmacy, the outcome of this research will be utilized to advance the level of pharmaceutical care within the community and improve health care literacy among patients.  The following projects are being conducted in our research facility in HPC2 and/or in collaboration with scientists from Oregon Health and Science University or University of Saskatchewan (Canada).

Project 1: Studying the Effect of Herbal Remedies on Drug Metabolizing Enzymes

Several animal studies (e.g. those of my postdoctoral research) and human clinical trials have demonstrated that consumption of some natural products decreases morbidity associated with chronic disease.  Therefore, public consumption of these products is expected to increase.  As a pharmacist, I find the increased use of natural products and nutraceuticals without consultation from the physician or pharmacist is concerning. Therefore in order to provide evidence-based consultation, more understanding of how these products (and their metabolites) affect the activity of drug metabolizing enzymes (DME) is needed.  This research focuses on filling this need by studying the bidirectional relationship between natural products and physiological systems. Induction or inhibition of DME by natural products can potentially affect bioavailability, and consequently, toxic effect of concomitantly administered medications. 

Project 2: Studying the Antihypertensive Effect of Sulforaphane in a Rat Hypertension Model

Substantial evidences indicate that metabolites of Arachidonic acid (AA) via kidney Cytochrome P450 (CYP) enzymes play a critical role in regulation of renal vascular tone, sodium transport, and may participate in the pathogenesis of hypertension.  20-hydroxyeicosatetraenoic acid (20-HETE) is one of the major AA products of CYP metabolism in the kidney.  In the renal and peripheral vasculature, 20-HETE is a potent vasoconstrictor that acts by depolarizing the vascular smooth muscles (VSM) cells.  Several studies have shown that the vasoconstriction response to vasoconstrictor agonists such as angiotensin II and norepinephrin is secondary to stimulating the endogenous production of 20-HETE in renal VSM cells.  In the rat; CYP4A1, CYP4A2 and CYP4A3 were found to exhibit the highest catalytic activity for the formation of 20-HETE. Therefore, specific inhibition of these CYP enzymes could be a potential target for prevention and/or treatment of hypertension mediated by elevation of 20-HETE formation.  Our lab is currently investigating the antihypertensive potential of Sulforaphane, the main active ingredient of broccoli sprouts and cruciferous vegetables.  We will investigate the potential inhibitory effect of Sulforaphane (SF) on the activity and expression of CYP enzymes involved in 20-HETE formation.

 

Publications

Book Chapters

Elbarbry F. Introduction to Toxicology. In: Karimi R, editor.Biomedical and Pharmaceutical Sciences with Patient Care Correlations. 2012 (in progress)

Elbarbry F and Karimi R. Introduction to Pharmacokinetics. In: Karimi R, editor. Biomedical and Pharmaceutical Sciences with Patient Care Correlations. 2012 (in progress)

Journal Articles

Ahmed H, Elbarbry F, Clark B. Mixed Micellar Electrokinetic Chromatographic Analysis of Colistin, a Polypeptide Antibiotic, Using Laser-Induced Fluorescence Detection. AJAC. 3:233-241. 2012.

Elbarbry F, Ragheb A, Marfleet T, and Shoker A.  Modulation of Hepatic Drug Metabolizing Enzymes by Dietary Doses of Thymoquinone in Female New Zealand White RabbitsPhytotherapy Research. 2012.

Karimi R,  Elbarbry F, Fortner J. Integrative Student Learning: An Effective Team Learning Activity in a Learner-Centered Paradigm.  Innovations in Pharmacy. 2(4):1-16. 2011

Elbarbry F and Elrody N. Potential Health Benefits of Sulforaphane: A Review of the Experimental, Clinical and Epidemiological Evidences and Underlying Mechanisms. JMPR. 5(4): 473-484. 2011

Elbarbry F, Chibbar R, Marfleet T, and Shoker A.  Cyclosporine-induced changes in drug metabolizing enzymes in hyperlipemic rabbit kidneys could explain its toxicity. Xenobiotica. 40(11):772-81. 2011

Karimi R, Arendt C, Elbarbry F, Roberts S.  Learning bridge: curricular integration of didactic and experiential education. AJPE. 74(3): article 48. 2010

Ragheb A, Attia A, Elbarbry F, Prasad K, Shoker A. Attenuated combined action of cyclosporine a and hyperlipidemia on atherogenesis in rabbits by thymoquinone. Evid Based Complement Alternat. Med.  2010

Elbarbry F, Attia A, Shoker A.  Validation of a new HPLC method for determination of midazolam and its metabolites: application to determine its pharmacokinetics in human and measure hepatic CYP3A activity in rabbitsJ Pharm Biomed Anal.  50(5):987-93. 2009

Ragheb A, Attia A, Elbarbry F, Shoker A. The protective effect of thymoquinone, an anti-oxidant and anti-inflammatory agent, against renal injury: a review. SJKDT. 20(5): 741-752. 2009

Elbarbry F and Alcorn J. Ontogeny of glutathione and glutathione-related antioxidant enzymes in rat liver. Research in Veterinary Sciences. 87(2):242-244. 2009

Ragheb A, Elbarbry F, Prasad K, Mohammed A, Shoker A.  Attenuation of the development of hypercholesterolemic atherosclerosis by thymoquinone. Int. J. Angiol. 17(4):186-192. 2008

Elbarbry F, Marfleet T, and Shoker A.  Drug-drug interactions with immunosuppressive agents: review of the in vitro functional assays and role of cytochrome P450 enzymes. Transplantation. 85(9), 1222-1229. 2008

Elbarbry F and Shoker A. Liquid chromatographic determination of mycophenolic acid and its metabolites in human kidney transplant plasma: pharmacokinetic application. J Chromatogr. B. 859(2):276-81. 2007

Elbarbry F and Shoker A.   Therapeutic drug measurement of mycophenolic acid derivatives in transplant patients. Clinical Biochemistry. 40(11):752-64. 2007

Elbarbry F, McNamara P, and Alcorn J.  Ontogeny of hepatic CYP1A2 and CYP2E1 expression in rat. J Biochem. Mol Toxicol. 21(1):41-50. 2007

Elbarbry F, Eldawy M, Mabrouk M. Determination of the analgesic components of Spasmomigraine tablet by liquid chromatography with ultraviolet detection. J AOAC Int. 90(1): 94-101. 2007

Alcorn J, Elbarbry F, and McNamara P.  Evaluation of the assumptions of an ontogeny model of rat hepatic cytochrome P450 activity. Drug Metabolism and Disposition. 35(12):2225-31. 2007

Elbarbry F and Shoker A.  Simple high performance liquid chromatographic assay for mycophenolic acid in renal transplant patientsJ Pharm. Biomed Anal. 43(2): 788-92. 2007

Elbarbry F, Wilby K, and Alcorn J. Validation of a HPLC method for the determination of p-nitrophenol hydroxylase activity in rat hepatic microsomesJ Chromatogr. B. 834 (1-2): 199-203. 2006

Elbarbry F and Alcorn J. Maturation of Cytochrome P450 2E1 and Glutathione-S-Transferases, Pharmacokinetic Model Validation, J Pharm. Pharmaceutical Sci., 7(2): 284-302. 2004

Eldawy M, Mabrouk M, and El-barbary F. Determination of chlorpheniramine maleate and tincture ipecac in dosage form by liquid chromatography with ultraviolet detection. J AOAC Int. 86 (4): 675-80. 2003

Eldawy M, Mabrouk M, and El-barbary FLiquid chromatographic determination of fluoxetine.  J Pharm Biomed Anal. 30 (3), 561-71. 2002

 

 

Back to Administration & Faculty Listing